Phase 1b Study of the Safety, Pharmacokinetics, and Disease-related Outcomes of the Matrix Metalloproteinase-9 Inhibitor Andecaliximab in Patients With Rheumatoid Arthritis.

Gossage, David L; Cieslarová, Blanka; Ap, Sophe; Zheng, Hao; Xin, Yan; Lal, Preeti; Chen, Guang; Smith, Victoria; Sundy, John S

Gossage, David L; Cieslarová, Blanka; Ap, Sophe; Zheng, Hao; Xin, Yan; Lal, Preeti; Chen, Guang; Smith, Victoria; Sundy, John S.

Affiliation

Gossage DL; Gilead Sciences, Inc, Foster City, California, USA. Electronic address: david.gossage@gilead.com.
Cieslarová B; Pharmaceutical Research Associates, CZ, s.r.o., Prague, Czech Republic.
Ap S; Gilead Sciences, Inc, Foster City, California, USA.
Zheng H; Gilead Sciences, Inc, Foster City, California, USA.
Xin Y; Gilead Sciences, Inc, Foster City, California, USA.
Lal P; Gilead Sciences, Inc, Foster City, California, USA.
Chen G; Gilead Sciences, Inc, Foster City, California, USA.
Smith V; Gilead Sciences, Inc, Foster City, California, USA.
Sundy JS; Gilead Sciences, Inc, Foster City, California, USA.

Clin Ther ; 40(1): 156-165.e5, 2018 01.

Article de En | MEDLINE | ID: mdl-29287749

Sujet(s)
Mots clés

autoimmune diseases; cartilage matrix; matrix metalloproteinase-9; pharmacokinetics; rheumatoid arthritis; therapeutic antibody

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Polyarthrite rhumatoïde / Antirhumatismaux / Inhibiteurs de métalloprotéinases matricielles / Anticorps monoclonaux Type d'étude: Clinical_trials / Prognostic_studies Limites: Aged / Female / Humans / Male / Middle aged Langue: En Journal: Clin Ther Année: 2018 Type de document: Article Pays de publication: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google